【摘要】 目的观察干扰素、拉米夫定、微卡、乙肝疫苗联合抗病毒疗法治疗慢性乙型肝炎的效果及作用机制。方法选择慢性乙型肝炎患者45例,随机分为联合抗病毒治疗组(干扰素、拉米夫定、微卡、乙肝疫苗联合治疗)20例和对照组(干扰素与拉米夫定联合治疗)25例,观察比较两组患者的ALT复常率、HBV DNA阴转率、HBeAg阴转率及e系统转换率。结果治疗组的肝功能复常率明显高于对照组(P<0.05);两组HBV DNA阴转率、HBeAg阴转率虽无显著性差异(P>0.05),但治疗组高于对照组,随着治疗时间的延长,这种趋势更加明显,并且6个月随访时治疗组的HBeAg阴转率明显高于对照组(P<0.05);治疗组的e系统转换率高于对照组,并且治疗12个月及6个月随访时这种差异具有显著性。结论联合抗病毒药与免疫调节剂治疗慢性乙型肝炎,能提高机体细胞免疫应答能力,增强抗病毒作用。更多还原

【Abstract】 Objective To investigate the efficacy of synthesized therapy of interferon-α1b,lamivudine,hepatitis B viral vaccine and vaccae in patients with chronic hepatitis B.Method Twenty patients with chronic hepatitis B received synthesized therapy of interferon-α1b,lamivudine,hepatitis B viral vaccine and vaccae and another twenty-five patients received interferon-α1b and lamivudine for six months.Result The alanine aminotrasaminase normalization,hepatitis B viral DNA loss and HBeAg/anti-Hbe seroconversion rate in synthesized group were higher than in control and at 6-month follow-up after the regimen,the difference between two group was statistically significant(P<0.05).Concusion The synthesized antiviral treatment gets a good result in our preliminary clinical trial.更多还原